Chronic Malignancies Working Party (CMWP)
Study type:
Study number:
42205686
Type of treatment:
Allogeneic
Diseases:
Myelodysplastic (MDS) or MDS/MPN
Short title:
MDS 2nd allo
Primary objective:
To analyse the frequencies, characteristics and outcome of patients with myelodysplastic syndrome undergoing a second allogeneic stem cell transplantation (alloSCT2) after relapse from a first allogeneic transplantation (alloSCT1) among centres in Europe.
Key inclusion criteria:
- adults (≥18 years)
- allogeneic SCT for MDS
- all patients that had undergone a second alloSCT after haematological, extramedullary or cytogenetic/molecular relapse, including relapse as sAML, after first allo-SCT between 01.01.2012 and 31.12.2021
- all types of conditioning
- all donor types[SC10.1]
- all types of GvHD-prophylaxis
- all stages at first and second transplant
- regardless of treatment before second SCT
- allogeneic SCT for MDS
- all patients that had undergone a second alloSCT after haematological, extramedullary or cytogenetic/molecular relapse, including relapse as sAML, after first allo-SCT between 01.01.2012 and 31.12.2021
- all types of conditioning
- all donor types[SC10.1]
- all types of GvHD-prophylaxis
- all stages at first and second transplant
- regardless of treatment before second SCT
Country:
All EBMT member countries
Principal investigator:
Giuliano Filippini Velazquez/Christoph Schmid
EBMT Study coordinator:
Laurien Baaij
Study coordinator email:
cmwp@ebmt.org
EBMT Study Unit:
Leiden Study Unit
Reason for processing personal data:
Research and Development of new and improved transplant, cell therapy and immunosuppression procedures.
Categories of personal data collected:
DOB/YOB, gender
Medical data already reported to the EBMT Registry
Recipients who may access the data:
Leiden Study Unit
Statistical Unit
Investigators
3rd-party processors of Personal Data on behalf of EBMT/Service provider:
No
Privacy notices
Article 6 lawful basis for processing personal data:
Article 6.1 (a) - Consent (Collection)
Article 9 basis for processing special category data:
Article 9(2) (a) - Consent (Collection)
Data Protection Impact Assessments
Rights available to individuals:
Access
Data portability
Rectification
Objection
Deletion
Is a Data Protection Impact Assessment required?:
DPIA performed for EBMT Registry (WP & NIS Studies)
Retention Schedule (if possible):
at least 5 years after the final report or first publication of study results